Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 4Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Melanoma 7Breast Neoplasms 6Colorectal Neoplasms 4Ovarian Neoplasms 3Neuroblastoma 3Neoplasm Metastasis 3Uveal Melanoma 2Unspecified Adult Solid Tumor, Protocol Specific 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Adenocarcinoma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Melphalan 16Dexamethasone 15Bortezomib 11Peripheral Blood Stem Cell Transplantation 9Lenalidomide 9fludarabine phosphate 8Calcium Dobesilate 7pomalidomide 5fludarabine 5Busulfan 5carfilzomib 4Radiotherapy 4Prednisone 4Cyclophosphamide 4liposomal doxorubicin 3daratumumab 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Filgrastim 3Cyclosporine 3Arsenic Trioxide 3Alemtuzumab 3samarium Sm-153 lexidronam 2holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 2Whole-Body Irradiation 2Surveys and Questionnaires 2Pneumococcal Vaccines 2Granulocyte Colony-Stimulating Factor 2Bendamustine Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Plasma Cell × sargramostim × Clear all
NCT00602706 2011-05-16

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Mayo Clinic

Phase 1/2 Completed
76 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡